journal
MENU ▼
Read by QxMD icon Read
search

Current Opinion in Allergy and Clinical Immunology

journal
https://www.readbyqxmd.com/read/30407207/strategies-to-reduce-corticosteroid-related-adverse-events-in-asthma
#1
Enrico Heffler, Diego Bagnasco, Giorgio Walter Canonica
PURPOSE OF REVIEW: Severe asthmatics, despite the chronic use of high inhaled corticosteroids (ICS) doses and frequent intake of systemic corticosteroids, remains clinically and/or functionally uncontrolled. These patients are also often affected by rhinitis or chronic rhinosinusitis requiring frequent use of intranasal corticosteroids. Therefore, severe asthmatics are exposed to an overload of corticosteroids that is frequently associated with relevant and costly adverse events. This clinical problem and the strategies to overcome it are here summarized...
November 6, 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30407206/interleukin-4-interleukin-13-versus-interleukin-5-a-comparison-of-molecular-targets-in-biologic-therapy-for-the-treatment-of-severe-asthma
#2
Albert Y Wu, Sanjiv Sur, J Andrew Grant, Julia W Tripple
PURPOSE OF REVIEW: Asthma is a chronic, inflammatory disorder of the airways caused by a complex interplay of various biologic mechanisms. Several monoclonal antibody therapies targeting interleukin (IL)-4/IL-13 and IL-5 cytokine pathways have been developed for the treatment of severe eosinophilic asthma. As individuals can display biomarkers and clinical features characteristic of several asthma phenotypes, selection of anoptimal biologic can be difficult. RECENT FINDINGS: Dupilumab, a monoclonal antibody that binds to the α subunit of the IL-4 receptor (IL-4Rα) and has been approved for the treatment of adults with severe atopic dermatitis, has been shown in recent phase 3 trials to also have significant clinical benefits in the asthmatic population irrespective of baseline eosinophil counts...
November 6, 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30394897/will-precision-medicine-be-available-for-all-patients-in-the-near-future
#3
René Maximiliano Gómez, Ignacio Ansotegui, Giorgio Walter Canonica
PURPOSE OF REVIEW: Evidence-based medicine and guidelines directing the diagnosis and treatment of patients are changing. General recommendations are moving towards an individual focus, where technology evolution allows identification of specific patterns and where 'one size fits all' no longer has a place. RECENT FINDINGS: Emerging innovations on health technology include useful tools for individualizing patients' specific conditions and follow-up. There are several preventive initiatives that aim to reduce allergic disease development, but they have no generalizable and definitive results as yet...
November 1, 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30299399/advances-in-site-specific-gene-editing-for-primary-immune-deficiencies
#4
Caroline Y Kuo
PURPOSE OF REVIEW: Conventional gene therapy has been a successful, curative treatment modality for many primary immune deficiencies with significant improvements in the last decade. However, the risk of leukemic transformation with viral-mediated gene addition still remains, and unregulated gene addition is not an option for certain diseases in which the target gene is closely controlled. The recent bloom in genome modification platforms has created the opportunity to site-specifically correct mutated DNA base pairs or insert a corrective cDNA minigene while maintaining gene expression under control of endogenous regulatory elements...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30299398/secondary-antibody-deficiency-in-neurology
#5
Emma C Tallantyre, Neil P Robertson, Stephen Jolles
PURPOSE OF REVIEW: Induction of lymphocyte depletion is increasingly used as a therapeutic strategy for central and peripheral neuroinflammatory disease. However, there is also a growing recognition of the treatment-related complication of secondary antibody deficiency (SAD). Although the occurrence of hypogammaglobulinaemia is a recognized phenomenon during immunomodulation, robust data on the coexistence of impaired responses to immunization, and significant and/or atypical infections is scarce...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30299397/biological-treatments-for-severe-asthma-where-do-we-stand
#6
William W Busse
PURPOSE OF REVIEW: For patients with severe asthma, disease control is not achieved resulting in persistent morbidity and risks for exacerbations. The advent of biologics is providing a new form of treatment for many with severe asthma. RECENT FINDINGS: Four mAb biologics are approved for clinical use: omalizumab (anti-IgE) and three antieosinophilic interventions (mepolizumab, reslizumab, and benralizumab). These four biologics target components of the type 2-inflammatory pathway which is reflected by biomarkers: peripheral blood eosinophils and exhaled nitric oxide...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30299396/very-early-onset-ibd-novel-genetic-aetiologies
#7
Vritika Batura, Aleixo M Muise
PURPOSE OF REVIEW: To summarize the current understanding and recent advances on the genetic aetiology in the pathogenesis of very early onset inflammatory bowel disease (VEO-IBD). RECENT FINDINGS: IBD is a chronic disorder of the gastrointestinal tract whose manifestation is a result of complex interactions between genetics, environment, immune system and microbial flora. Over 230 IBD risk loci have been reported in genome wide association studies but the genetic contribution of the majority of these loci in the manifestation of IBD is very low...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30299395/very-early-onset-inflammatory-bowel-disease-an-integrated-approach
#8
Kathleen E Sullivan, Maire Conrad, Judith R Kelsen
PURPOSE OF REVIEW: Immune dysregulation disorders are among the most rapidly growing set of inborn errors of immunity. One particular subset is the category where early-onset inflammatory bowel disease (IBD) is the most common manifestation. These disorders are being increasingly appreciated although there has been minimal effort to articulate a unified approach to their diagnosis and management. This review will cover current thinking and strategies related to diagnosis and management of very early-onset IBD...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30199379/nasal-challenges-in-allergen-immunotherapy-trials
#9
Mark W Tenn, Matthew Rawls, Anne K Ellis
PURPOSE OF REVIEW: The nasal allergen challenge (NAC) model can be a valuable diagnostic tool for allergic rhinitis. Alongside its clinical use, NACs can be used as primary and secondary endpoints in studies evaluating allergen immunotherapy (AIT) products for allergic rhinitis treatment. This review will discuss the technical aspects of the NAC model and provide a summary of recent studies using NACs to assess existing and new AIT treatments. RECENT FINDINGS: Over the last 2 years, both titrated and single-dose nasal challenge protocols have been used to evaluate immunotherapies targeting grass, birch, house dust mite, and cat allergens...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30188342/what-is-new-in-hies-recent-insights-from-the-interface-of-primary-immune-deficiency-and-atopy
#10
Mark J Ponsford, William Rae, Adam Klocperk
PURPOSE OF REVIEW: Understanding the pathophysiology of monogenic primary immunodeficiency (PID) with atopic presentation has pivotal implications for intervention strategies and potentially wider polygenic atopic-related traits. This review will discuss advances in gene discovery arising from monogenic defects at the interface between PID and atopy, notably the hyper-IgE syndromes. RECENT FINDINGS: Key molecular pathways underlying development of primary atopic diseases have recently been proposed...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30148718/allergen-immunotherapy-as-add-on-to-biologic-agents
#11
Carlo Lombardi, Giorgio W Canonica, Giovanni Passalacqua
PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT). RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30124489/role-of-allergen-specific-t-follicular-helper-cells-in-immunotherapy
#12
Yin Yao, Zhi-Chao Wang, Di Yu, Zheng Liu
PURPOSE OF REVIEW: The discovery of novel T-cell subsets including follicular helper T (Tfh) cells has broadened our knowledge on the complex immune networks in allergic diseases. This review summarizes the evidence for Tfh cells in controlling immune responses to allergens with a particular focus on immunoglobulin E (IgE) production and discusses the implication of such regulation in allergen-specific immunotherapy. RECENT FINDINGS: Tfh cells support the production of IgE in animal models for allergic diseases...
December 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30113329/noninvasive-measures-in-atopic-dermatitis
#13
Joachim W Fluhr, Torsten Zuberbier, Razvigor Darlenski
PURPOSE OF REVIEW: To summarize the current knowledge on the morphology, functionality and biochemical composition of the skin in allergic reactions. We address novel noninvasive techniques that promise to disclose intimate mechanisms of skin allergy in vivo. Epidermal barrier is not just a static wrap of the organism but rather a dynamic field for immunological, biophysical and biochemical processes and serves as a bio-sensor for exogenous danger signals. RECENT FINDINGS: Classical biophysical methods are amended by novel in-vivo techniques, such as Raman spectroscopy, analysing the skin microcomposition and develop epidermal profiles...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30095475/novel-systemic-drugs-in-treatment-of-atopic-dermatitis-results-from-phase-ii-and-phase-iii-studies-published-in-2017-2018
#14
Thomas Werfel
PURPOSE OF REVIEW: The present review will give an update of recently published clinical studies on novel systemic treatment approaches in atopic dermatitis. RECENT FINDINGS: Until 2017 immunosuppressive drugs such as cyclosporine had to be used in atopic dermatitis when the disease could not sufficiently be treated with topical drugs. Several new substances specifically targeting inflammation in atopic dermatitis are currently studied. In 2017, dupilumab was approved in the United States and in Europe for first-line biologic treatment of moderate to severe atopic dermatitis in adults...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30048251/phenotypes-endotypes-and-biomarkers-in-anaphylaxis-current-insights
#15
Anna Sala-Cunill, Mar Guilarte, Victoria Cardona
PURPOSE OF REVIEW: The aim of the review is to describe the different clinical pictures of anaphylaxis (phenotypes), in relation to the underlying mechanisms and potential biomarkers, to describe anaphylaxis endotypes. This may aid in achieving a better understanding, management and outcomes of such severe reactions. RECENT FINDINGS: Different anaphylaxis phenotypes have been outlined, ranging from the classical type-I-like to those suggestive of cytokine-storm-like or complement-mediated reactions...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30028728/pitfalls-in-anaphylaxis
#16
Giulia De Feo, Roberta Parente, Massimo Triggiani
PURPOSE OF REVIEW: Anaphylaxis is an acute medical emergency characterized by sudden presentation of life-threatening respiratory and cardiovascular symptoms. Rapid diagnosis of anaphylaxis is crucial to implement an appropriate treatment and management plan. However, mistakes in the diagnosis of anaphylaxis may occur because of the limited time during which the diagnosis must be made, the stressful environment of the emergency room, the often aspecific or incomplete clinical features of early anaphylaxis and the lack of useful laboratory markers...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30020260/globalization-and-anaphylaxis
#17
Luciana Kase Tanno, Ignacio Ansotegui, Pascal Demoly
PURPOSE OF REVIEW: To understand the impact of globalization in the management of anaphylaxis and identify potential strategies to improve patients' care and prevention. RECENT FINDINGS: Developments in the field of anaphylaxis have been consistently following these globalization trends offering possibilities of collaborations of the allergy community and integrated international initiatives to reach quality care of allergic patients worldwide. SUMMARY: Globalization is the process of interaction and integration between people, companies, and governments worldwide...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30020259/adults-and-children-with-anaphylaxis-in-the-emergency-room-why-it-is-not-recognized
#18
Marcelo V Aun, Jorge Kalil, Pedro Giavina-Bianchi
PURPOSE OF REVIEW: Despite many international guidelines have been published in the last 10 years, anaphylaxis continues to be underdiagnosed, undernotified, and undertreated. Anaphylactic reactions in adults and children in emergency departments are frequently not recognized, leading to underutilization of epinephrine, and a higher risk of death. RECENT FINDINGS: A few studies have been recently published showing that educational intervention for both physicians and other healthcare professionals improve diagnosis and treatment of anaphylaxis...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30020258/topical-antihistamines-mast-cell-stabilizers-and-dual-action-agents-in-ocular-allergy-current-trends
#19
Hadas Ben-Eli, Abraham Solomon
PURPOSE OF REVIEW: To address the current trends of therapeutic mechanisms for treatment of allergic conjunctivitis (AC), based on topical antihistamines and mast cell stabilizers (MCS). RECENT FINDINGS: The antihistamine drug alcaftadine has H4 receptor inverse agonism, anti-inflammatory and MCS activities. The antihistamines levocabastine and azelastine are more effective than placebo in treatment of AC symptoms in randomized controlled trials (RCTs). The topical dual-action antihistamines/MCS olopatadine, azelastine, ketotifen, and epinastine are commonly used in Europe and in the United States for mild subtypes of AC...
October 2018: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/30020257/seasonal-ocular-allergy-and-pollen-counts
#20
Arianna Prince, Matthew R Norris, Leonard Bielory
PURPOSE OF REVIEW: The purpose of the article is to provide a historical overview of literature regarding pollen sensitization and ocular allergy with an emphasis on developments that have occurred over the past 5 years. RECENT FINDINGS: Currently, pollen studies have examined the molecular and cellular pathways involved in initiating allergic conjunctivitis to find targets for therapeutics. Studies have also documented the threshold, linear increase and plateau point in the relationship between pollen levels and allergic conjunctivitis symptoms...
October 2018: Current Opinion in Allergy and Clinical Immunology
journal
journal
20090
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"